表紙：緑膿菌感染症治療市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

市場調査レポート

商品コード

1140654

緑膿菌感染症治療市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Pseudomonas Aeruginosa Infection Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

出版日: 2022年08月09日 | 発行: Transparency Market Research

| ページ情報: 英文 212 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 5,795 910,626円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Multi-user License)

USD 8,795 1,382,046円

レポートPDFを同一の部署内・課内の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Corporate License)

USD 11,795 1,853,466円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の緑膿菌感染症治療市場について調査し、市場の概要とともに、2022年～2031年の予測、治療タイプ別、薬剤タイプ別、塘路経路別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 01: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017-2031
Table 02: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 03: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 04: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 05: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017-2031
Table 08: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 09: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 10: North America Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 11: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017-2031
Table 13: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 14: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 15: Europe Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 16: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017-2031
Table 18: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 19: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 20: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017-2031
Table 23: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 24: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 25: Latin America Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 26: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017-2031
Table 28: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 29: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 30: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Pseudomonas Aeruginosa Infection Treatment Market, by Medication Type, 2021 and 2031
Figure 02: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022-2031
Figure 03: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Monotherapy, 2017-2031
Figure 04: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Combination Therapy, 2017-2031
Figure 05: Global Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031
Figure 06: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
Figure 07: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Aminoglycoside, 2017-2031
Figure 08: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Cephalosporin, 2017-2031
Figure 09: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Carbapenem, 2017-2031
Figure 10: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Monobactam, 2017-2031
Figure 11: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Others, 2017-2031
Figure 12: Global Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031
Figure 13: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 14: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Nasal, 2017-2031
Figure 15: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Oral, 2017-2031
Figure 16: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Intravenous, 2017-2031
Figure 17: Global Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031
Figure 18: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 19: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Hospital Pharmacies, 2017-2031
Figure 20: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 21: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Online Pharmacies, 2017-2031
Figure 22: Global Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Region, 2021 and 2031
Figure 23: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Region, 2022-2031
Figure 24: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 25: North America Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 26: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country, 2022-2031
Figure 27: North America Pseudomonas Aeruginosa Infection Treatment Market, by Medication Type, 2021 and 2031
Figure 28: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022-2031
Figure 29: North America Pseudomonas Aeruginosa Infection Treatment Market , by Drug Type, 2021 and 2031
Figure 30: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
Figure 31: North America Pseudomonas Aeruginosa Infection Treatment Market , by Route of Administration, 2021 and 2031
Figure 32: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 33: North America Pseudomonas Aeruginosa Infection Treatment Market , by Distribution Channel, 2021 and 2031
Figure 34: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 35: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 36: Europe Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 37: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 38: Europe Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031
Figure 39: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022-2031
Figure 40: Europe Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031
Figure 41: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
Figure 42: Europe Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031
Figure 43: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 44: Europe Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031
Figure 45: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 46: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 47: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 48: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 49: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031
Figure 50: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022-2031
Figure 51: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031
Figure 52: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
Figure 53: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031
Figure 54: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 55: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031
Figure 56: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Distribution Channel, 2022-2031
Figure 57: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 58: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 59: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 60: Latin America Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031
Figure 61: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022-2031
Figure 62: Latin America Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031
Figure 63: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
Figure 64: Latin America Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031
Figure 65: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 66: Latin America Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031
Figure 67: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 68: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 69: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 70: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 71: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031
Figure 72: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022-2031
Figure 73: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031
Figure 74: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
Figure 75: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031
Figure 76: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 77: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031
Figure 78: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031

Product Code: TMRGL17156

The report provides revenue of the global pseudomonas aeruginosa infection treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pseudomonas aeruginosa infection treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pseudomonas aeruginosa infection treatment market.

The report delves into the competitive landscape of the global pseudomonas aeruginosa infection treatment market. Key players operating in the global pseudomonas aeruginosa infection treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global pseudomonas aeruginosa infection treatment market profiled in this report.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Pseudomonas Aeruginosa Infection Treatment Market

4. Market Overview

4.1. Introduction
- 4.1.1. Medication Type Definition
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecasts, 2017 - 2031
- 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Diseases Epidemiology
5.2. Pricing Analysis
5.3. Regulatory Scenario
5.4. Reimbursement Scenario by Region/globally
5.5. COVID-19 Impact Analysis

6. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Medication Type

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Medication Type, 2017 - 2031
- 6.3.1. Monotherapy
- 6.3.2. Combination Therapy
6.4. Market Attractiveness, by Medication Type

7. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Drug Type

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Type, 2017 - 2031
- 7.3.1. Aminoglycoside
- 7.3.2. Cephalosporin
- 7.3.3. Carbapenem
- 7.3.4. Monobactam
- 7.3.5. Others
7.4. Market Attractiveness, by Drug Type

8. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Route of Administration

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017 - 2031
- 8.3.1. Nasal
- 8.3.2. Oral
- 8.3.3. Intravenous
8.4. Market Attractiveness, by Route of Administration

9. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Distribution Channel

9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies
- 9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel

10. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Region

10.1. Key Findings
10.2. Market Value Forecast, by Region
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Country/Region

11. North America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Medication Type, 2017 - 2031
- 11.2.1. Monotherapy
- 11.2.2. Combination Therapy
11.3. Market Value Forecast, by Drug Type, 2017 - 2031
- 11.3.1. Aminoglycoside
- 11.3.2. Cephalosporin
- 11.3.3. Carbapenem
- 11.3.4. Monobactam
- 11.3.5. Others
11.4. Market Value Forecast, by Route of Administration, 2017 - 2031
- 11.4.1. Nasal
- 11.4.2. Oral
- 11.4.3. Intravenous
11.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
- 11.5.1. Hospital Pharmacies
- 11.5.2. Retail Pharmacies
- 11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2017 - 2031
- 11.6.1. U.S.
- 11.6.2. Canada
11.7. Market Attractiveness Analysis
- 11.7.1. By Medication Type
- 11.7.2. By Drug Type
- 11.7.3. By Route of Administration
- 11.7.4. By Distribution Channel
- 11.7.5. By Country

12. Europe Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Medication Type, 2017 - 2031
- 12.2.1. Monotherapy
- 12.2.2. Combination Therapy
12.3. Market Value Forecast, by Drug Type, 2017 - 2031
- 12.3.1. Aminoglycoside
- 12.3.2. Cephalosporin
- 12.3.3. Carbapenem
- 12.3.4. Monobactam
- 12.3.5. Others
12.4. Market Value Forecast, by Route of Administration, 2017 - 2031
- 12.4.1. Nasal
- 12.4.2. Oral
- 12.4.3. Intravenous
12.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
- 12.5.1. Hospital Pharmacies
- 12.5.2. Retail Pharmacies
- 12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country, 2017 - 2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Spain
- 12.6.5. Italy
- 12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
- 12.7.1. By Medication Type
- 12.7.2. By Drug Type
- 12.7.3. By Route of Administration
- 12.7.4. By Distribution Channel
- 12.7.5. By Country/Sub-region

13. Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Medication Type, 2017 - 2031
- 13.2.1. Monotherapy
- 13.2.2. Combination Therapy
13.3. Market Value Forecast, by Drug Type, 2017 - 2031
- 13.3.1. Aminoglycoside
- 13.3.2. Cephalosporin
- 13.3.3. Carbapenem
- 13.3.4. Monobactam
- 13.3.5. Others
13.4. Market Value Forecast, by Route of Administration, 2017 - 2031
- 13.4.1. Nasal
- 13.4.2. Oral
- 13.4.3. Intravenous
13.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
- 13.5.1. Hospital Pharmacies
- 13.5.2. Retail Pharmacies
- 13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country, 2017 - 2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
- 13.7.1. By Medication Type
- 13.7.2. By Drug Type
- 13.7.3. By Route of Administration
- 13.7.4. By Distribution Channel
- 13.7.5. By Country/Sub-region

14. Latin America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Medication Type, 2017 - 2031
- 14.2.1. Monotherapy
- 14.2.2. Combination Therapy
14.3. Market Value Forecast, by Drug Type, 2017 - 2031
- 14.3.1. Aminoglycoside
- 14.3.2. Cephalosporin
- 14.3.3. Carbapenem
- 14.3.4. Monobactam
- 14.3.5. Others
14.4. Market Value Forecast, by Route of Administration, 2017 - 2031
- 14.4.1. Nasal
- 14.4.2. Oral
- 14.4.3. Intravenous
14.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
- 14.5.1. Hospital Pharmacies
- 14.5.2. Retail Pharmacies
- 14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country, 2017 - 2031
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
- 14.7.1. By Medication Type
- 14.7.2. By Drug Type
- 14.7.3. By Route of Administration
- 14.7.4. By Distribution Channel
- 14.7.5. By Country/Sub-region

15. Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Medication Type, 2017 - 2031
- 15.2.1. Monotherapy
- 15.2.2. Combination Therapy
15.3. Market Value Forecast, by Drug Type, 2017 - 2031
- 15.3.1. Aminoglycoside
- 15.3.2. Cephalosporin
- 15.3.3. Carbapenem
- 15.3.4. Monobactam
- 15.3.5. Others
15.4. Market Value Forecast, by Route of Administration, 2017 - 2031
- 15.4.1. Nasal
- 15.4.2. Oral
- 15.4.3. Intravenous
15.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
- 15.5.1. Hospital Pharmacies
- 15.5.2. Retail Pharmacies
- 15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country, 2017 - 2031
- 15.6.1. GCC Countries
- 15.6.2. South Africa
- 15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
- 15.7.1. By Medication Type
- 15.7.2. By Drug Type
- 15.7.3. By Route of Administration
- 15.7.4. By Distribution Channel
- 15.7.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Company Profiles
- 16.2.1. ALLERGAN
  - 16.2.1.1. Company Description
  - 16.2.1.2. Business Overview
  - 16.2.1.3. Financial Overview
  - 16.2.1.4. Strategic Overview
  - 16.2.1.5. SWOT Analysis
- 16.2.2. Teva Pharmaceutical Industries Ltd.
  - 16.2.2.1. Company Description
  - 16.2.2.2. Business Overview
  - 16.2.2.3. Financial Overview
  - 16.2.2.4. Strategic Overview
  - 16.2.2.5. SWOT Analysis
- 16.2.3. Pfizer Inc.
  - 16.2.3.1. Company Description
  - 16.2.3.2. Business Overview
  - 16.2.3.3. Financial Overview
  - 16.2.3.4. Strategic Overview
  - 16.2.3.5. SWOT Analysis
- 16.2.4. Lupin Pharmaceuticals, Inc.
  - 16.2.4.1. Company Description
  - 16.2.4.2. Business Overview
  - 16.2.4.3. Financial Overview
  - 16.2.4.4. Strategic Overview
  - 16.2.4.5. SWOT Analysis
- 16.2.5. AstraZeneca
  - 16.2.5.1. Company Description
  - 16.2.5.2. Business Overview
  - 16.2.5.3. Financial Overview
  - 16.2.5.4. Strategic Overview
  - 16.2.5.5. SWOT Analysis
- 16.2.6. Merck & Co., Inc.
  - 16.2.6.1. Company Description
  - 16.2.6.2. Business Overview
  - 16.2.6.3. Financial Overview
  - 16.2.6.4. Strategic Overview
  - 16.2.6.5. SWOT Analysis
- 16.2.7. Bristol-Myers Squibb Co.
  - 16.2.7.1. Company Description
  - 16.2.7.2. Business Overview
  - 16.2.7.3. Financial Overview
  - 16.2.7.4. Strategic Overview
  - 16.2.7.5. SWOT Analysis
- 16.2.8. Janssen Pharmaceuticals, Inc.
  - 16.2.8.1. Company Description
  - 16.2.8.2. Business Overview
  - 16.2.8.3. Financial Overview
  - 16.2.8.4. Strategic Overview
  - 16.2.8.5. SWOT Analysis

緑膿菌感染症治療市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Pseudomonas Aeruginosa Infection Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

目次

第1章序文

第2章前提と調査手法

第3章エグゼクティブサマリー：世界の緑膿菌感染症治療市場

第4章市場概要

第5章主な洞察

第6章世界の緑膿菌感染治療市場の分析と予測、治療タイプ別

第7章世界の緑膿菌感染治療市場の分析と予測、薬剤タイプ別

第8章世界の緑膿菌感染治療市場の分析と予測、投与経路別

第9章世界の緑膿菌感染治療市場の分析と予測、流通チャネル別

第10章世界の緑膿菌感染治療市場の分析と予測、地域別

第11章北米の緑膿菌感染治療市場の分析と予測

第12章欧州の緑膿菌感染治療市場の分析と予測

第13章アジア太平洋の緑膿菌感染治療市場の分析と予測

第14章ラテンアメリカの緑膿菌感染治療市場の分析と予測

第15章中東・アフリカの緑膿菌感染治療市場の分析と予測

第16章競合情勢

List of Tables

List of Figures

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary : Global Pseudomonas Aeruginosa Infection Treatment Market

4. Market Overview

5. Key Insights

6. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Medication Type

7. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Drug Type

8. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Route of Administration

9. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Distribution Channel

10. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Region

11. North America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

12. Europe Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

13. Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

14. Latin America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

15. Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

16. Competition Landscape

緑膿菌感染症治療市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Pseudomonas Aeruginosa Infection Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界の緑膿菌感染症治療市場

第4章 市場概要

第5章 主な洞察

第6章 世界の緑膿菌感染治療市場の分析と予測、治療タイプ別

第7章 世界の緑膿菌感染治療市場の分析と予測、薬剤タイプ別

第8章 世界の緑膿菌感染治療市場の分析と予測、投与経路別

第9章 世界の緑膿菌感染治療市場の分析と予測、流通チャネル別

第10章 世界の緑膿菌感染治療市場の分析と予測、地域別

第11章 北米の緑膿菌感染治療市場の分析と予測

第12章 欧州の緑膿菌感染治療市場の分析と予測

第13章 アジア太平洋の緑膿菌感染治療市場の分析と予測

第14章 ラテンアメリカの緑膿菌感染治療市場の分析と予測

第15章 中東・アフリカの緑膿菌感染治療市場の分析と予測

第16章 競合情勢

List of Tables

List of Figures

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary : Global Pseudomonas Aeruginosa Infection Treatment Market

4. Market Overview

5. Key Insights

6. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Medication Type

7. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Drug Type

8. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Route of Administration

9. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Distribution Channel

10. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Region

11. North America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

12. Europe Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

13. Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

14. Latin America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

15. Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

16. Competition Landscape

第1章序文

第2章前提と調査手法

第3章エグゼクティブサマリー：世界の緑膿菌感染症治療市場

第4章市場概要

第5章主な洞察

第6章世界の緑膿菌感染治療市場の分析と予測、治療タイプ別

第7章世界の緑膿菌感染治療市場の分析と予測、薬剤タイプ別

第8章世界の緑膿菌感染治療市場の分析と予測、投与経路別

第9章世界の緑膿菌感染治療市場の分析と予測、流通チャネル別

第10章世界の緑膿菌感染治療市場の分析と予測、地域別

第11章北米の緑膿菌感染治療市場の分析と予測

第12章欧州の緑膿菌感染治療市場の分析と予測

第13章アジア太平洋の緑膿菌感染治療市場の分析と予測

第14章ラテンアメリカの緑膿菌感染治療市場の分析と予測

第15章中東・アフリカの緑膿菌感染治療市場の分析と予測

第16章競合情勢